Table 5 FDA-approved immunotherapy in advanced/metastatic NSCLC
From: Emerging therapeutic agents for advanced non-small cell lung cancer
Drug | Class | Month/year | Indication(s) |
|---|---|---|---|
Nivolumab (OPDIVO) | Anti-PD-1 | March/2015 | Metastatic squamous NSCLC with progression on or after platinum-based chemotherapy. |
October/2015 | Metastatic NSCLC in patients with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. | ||
Pembrolizumab (KEYTRUDA) | Anti-PD1 | October/2015 | Metastatic NSCLC whose tumors express PD-L1 (TPS ≥ 1%) with progression or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. |
October/2016 | NSCLC whose tumors have high PD-L1 expression (TPS ≥ 50%), with no EGFR or ALK genomic tumor aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC. | ||
May/2017 | In combination with pemetrexed and carboplatin, as first-line treatment of patients with metastatic non-squamous NSCLC and with no EGFR or ALK genomic tumor aberrations. | ||
October/2018 | In combination with carboplatin and either paclitaxel or nabpaclitaxel, as first-line treatment of patients with metastatic squamous NSCLC. | ||
April/2019 | Single agent for the first-line treatment of patients with stage III NSCLC, who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC, and whose tumors express PD-L1 [tumor proportion score (TPS) ≥ 1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. | ||
Atezolizumab (TECENTRIQ) | Anti-PD-L1 | October/2016 | Metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving TECENTRIQ. |
December/2018 | In combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. | ||
December/2019 | In combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. |